Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 40

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 40
---
 statement contained in this prospectus or in any other subsequently filed document which also is or is deemed to
be incorporated by reference in this prospectus modifies or supersedes that statement. Any statement that is modified or superseded will
not constitute a part of this prospectus, except as modified or superseded.

<div align='center'>S-24</div>

PROSPECTUS

<div align='center'>ENDRA Life Sciences Inc.

$50,000,000

Common Stock

Preferred Stock

Debt Securities

Warrants

Units</div>

This prospectus relates to common stock, preferred
stock, debt securities, warrants and units that ENDRA Life Sciences Inc. may sell from time to time in one or more offerings on terms
to be determined at the time of sale. We will provide specific terms of these securities in supplements to this prospectus. You should
read this prospectus and any supplement carefully before you invest. This prospectus may not be used to offer and sell securities unless
accompanied by a prospectus supplement for those securities.

These securities may be sold directly by us, through
dealers or agents designated from time to time, to or through underwriters or through a combination of these methods. See “Plan
of Distribution” in this prospectus. We may also describe the plan of distribution for any particular offering of these securities
in any applicable prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect
of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus
supplement. The net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.

Our common stock trades on the Nasdaq Capital
Market under the symbol “NDRA.” On February 13, 2024, the last reported sale price for our common stock was $1.12 per share.

As of February 14, 2024, the aggregate market
value of our outstanding common stock held by non-affiliates was $27,200,435 based on 11,035,659 shares of outstanding common stock, of
which 10,880,174 shares are held by non-affiliates, and the last reported sale price of our common stock of $2.50 per share on December
22, 2023. Pursuant to General Instruction 1.B.6 of Form S-3, in no event will we